• 1. An ionic liquid-mesoporous silica blend as a novel adsorbent for the adsorption and recovery of palladium ions, and its applications in continuous flow study and as an industrial catalyst?
  Shivani Sharma,Chia-Ming Wu,Ranjit T. Koodali,N. Rajesh RSC Adv., 2016,6, 26668-26678
• 2. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 3. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 4. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 5. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644

Introduction to 2-(3,4-Dimethylphenoxy)methylbenzoic Acid (CAS No. 77389-77-6)

2-(3,4-Dimethylphenoxy)methylbenzoic acid, identified by its Chemical Abstracts Service (CAS) number 77389-77-6, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic research. This compound belongs to the class of benzoic acid derivatives, characterized by its unique structural motif that combines a benzoic acid backbone with a phenoxymethyl side chain substituted with dimethyl groups at the ortho positions of the phenyl ring. The presence of these functional groups imparts distinct chemical and pharmacological properties, making it a valuable scaffold for drug discovery and molecular pharmacology studies.

The structure of 2-(3,4-Dimethylphenoxy)methylbenzoic acid consists of a central benzene ring substituted with a carboxylic acid group at one position and a phenoxymethyl group at another. The phenoxymethyl group itself is further modified by two methyl groups at the 3rd and 4th positions relative to the oxygen atom, enhancing its lipophilicity and potential for interactions with biological targets. This structural configuration not only influences its solubility and metabolic stability but also plays a crucial role in its biological activity, as evidenced by recent advancements in medicinal chemistry.

In recent years, benzoic acid derivatives have been extensively explored due to their diverse biological activities and favorable pharmacokinetic profiles. Among these derivatives, compounds featuring a phenoxymethyl moiety have shown promise in modulating various cellular pathways, including inflammatory responses, pain perception, and enzyme inhibition. The dimethylation of the phenyl ring in 2-(3,4-Dimethylphenoxy)methylbenzoic acid is particularly noteworthy, as it fine-tunes the electronic properties of the aromatic system, thereby affecting its binding affinity to biological targets.

One of the most compelling aspects of 2-(3,4-Dimethylphenoxy)methylbenzoic acid is its potential application in the development of novel therapeutic agents. Current research indicates that this compound exhibits inhibitory activity against certain enzymes implicated in chronic inflammatory diseases and neurodegenerative disorders. For instance, studies have suggested that it may interact with cyclooxygenase (COX) enzymes, which are key players in prostaglandin synthesis—a pathway central to inflammation and pain mediation. The structural features of this compound allow it to mimic natural substrates or modulators of these enzymes, potentially leading to the discovery of new drugs with improved efficacy and reduced side effects.

The synthesis of 2-(3,4-Dimethylphenoxy)methylbenzoic acid typically involves multi-step organic reactions starting from commercially available precursors such as dimethylanisole and benzoic acid derivatives. Advanced synthetic methodologies, including palladium-catalyzed cross-coupling reactions and selective functional group transformations, have been employed to achieve high yields and purity. These synthetic strategies not only facilitate access to this compound but also provide insights into optimizing its structural analogs for enhanced biological activity.

From a biological perspective, the dimethoxy substitution pattern on the phenoxy ring is critical for determining the compound's pharmacological profile. Computational modeling studies have demonstrated that this substitution enhances binding interactions with specific protein targets by improving hydrophobic complementarity and electronic coupling. Such insights are invaluable for rational drug design, allowing medicinal chemists to predict how modifications to the core structure will influence biological outcomes.

Recent preclinical studies have highlighted the therapeutic potential of 2-(3,4-Dimethylphenoxy)methylbenzoic acid in models of inflammation and pain. In vitro assays have revealed its ability to suppress inflammatory cytokine production in immune cells while exhibiting low toxicity profiles. These findings align with emerging evidence suggesting that benzoic acid derivatives can modulate immune responses through mechanisms involving nuclear factor kappa B (NF-κB) signaling pathways. The dimethoxy group appears to play a pivotal role in this modulation by selectively interacting with residues within protein binding pockets.

The pharmacokinetic properties of 2-(3,4-Dimethylphenoxy)methylbenzoic acid are another area of active investigation. Due to its moderate lipophilicity facilitated by the dimethylanisyl side chain, this compound is expected to exhibit reasonable oral bioavailability. However, its metabolic stability remains a critical factor that could influence its clinical utility; further studies are needed to assess its degradation pathways in vivo. Advances in metabolomics have enabled researchers to monitor drug metabolism more precisely than ever before, providing critical data on how this compound is processed within biological systems.

In conclusion,2-(3,4-Dimethylphenoxy)methylbenzoic acid (CAS No. 77389-77-6) represents an intriguing example of how structural modifications can enhance biological activity while maintaining favorable pharmacokinetic characteristics. Its unique combination of chemical features makes it a promising candidate for further exploration in drug discovery programs targeting inflammation-related diseases as well as other therapeutic areas where enzyme inhibition is relevant. As research continues into this class of compounds,future directions may include exploring derivative libraries designed around this scaffold—leveraging computational tools such as virtual screening—to identify next-generation candidates with optimized properties for clinical translation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)